2026. CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A Prospective, Non-Interventional Study of the Safety and Effectiveness of Cemiplimab in Immunocompromised/Immunosuppressed Patients With Advanced Cutaneous Squamous Cell Carcinoma at 2 Years’ Follow-Up. SKIN The Journal of Cutaneous Medicine. 10, 2 (Mar. 2026), s756. DOI:https://doi.org/10.25251/hex0h755.